Altimmune, Inc. (ALT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.97-7.08%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ALT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 176.6% |
| Our one-year growth estimate | diamond | 91.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 84.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
ALT — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-10-29
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment to Loan and Security Agreement, dated as of November 5, 2025, the “Loan Agreement”), with Hercules Capital, Inc., and other lenders party thereto,…
Why it matters: FDA feedback will show whether Altimmune has a clear next step for its AUD program.
Watch forAltimmune reports an FDA meeting and a clear path to the next AUD trial, with registrational endpoints named.
Also watch forThe FDA asks for more Phase 2 data, or Altimmune reports no clear trial path.
Why it matters: PERFORMA is the main test of pemvidutide in MASH. Delays or trial problems would slow this program.
Watch forAltimmune says PERFORMA enrollment is on plan. No major safety issues or trial delays have occurred.
Also watch forAltimmune reports a PERFORMA delay, a safety issue, or a change that weakens the trial.
Why it matters: The new directors bring drug launch and deal experience. Their actions may show how Altimmune plans to develop pemvidutide.
Watch forAfter joining on November 2, the board sets a clear plan for development, partnerships, or sales.
Also watch forThe board reports no change in its plan, or the company delays a named development step.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$203 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $570 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,812 loss on $10,000 · 68.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.